The following companies have increased their investments in fixed assets significantly over recent years, with the target to upgrade their operating activities. This may signal that these companies believe demand for their goods and services will increase in the near future, producing higher sales.

Wall Street sell-side analysts also recommend these stocks and have issued positive ratings.

Co-Diagnostics Inc

The first company which investors may be interested in is Co-Diagnostics Inc (CODX), a Salt Lake City, Utah-based manufacturer and seller of reagents used for nucleic acid testing.

Co-Diagnostics Inc invested $113,246 in the purchase of property and equipment in

As economic and market fallout from the coronavirus outbreak intensified this week, so has the sense of urgency felt by many investors. Several days saw selling that can only be described as panicked, as circuit breakers on U.S. stock exchanges were tripped up on two several occasions.

Investors looking to hedge their bets and minimize losses are turning to pharma and biotech stocks, but there is a catch here. Many anti-viral pharmaceutical companies working on vaccines for the coronavirus are not really gaining much steam owing to the long-term duration for a vaccine to develop. The three subsectors which appear

The U.S. stock indices are filled with small pharma and biotech stocks that are purely research-oriented. Most of these companies don’t even have revenues and are entirely focused on building a strong pipeline of drugs and vaccines to counter various diseases that are affecting mankind.

The problem with these companies is that their low or nonexistent revenues result in a weak investor perception as the qualitative benefits of their research cannot be measured tangibly. However, with the outbreak of the Wuhan coronavirus, the importance of investing in the research of such companies is suddenly a hot topic in the investor